Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Toll-like receptor 2 expression level on monocytes in patients with viral infections: monitoring infection severity.

Authors: Kajiya, T  Orihara, K  Hamasaki, S  Oba, R  Hirai, H  Nagata, K  Kumagai, T  Ishida, S  Oketani, N  Ichiki, H  Kuwahata, S  Fujita, S  Uemura, N  Tei, C 
Citation: Kajiya T, etal., J Infect. 2008 Sep;57(3):249-59. Epub 2008 Jul 26.
Pubmed: (View Article at PubMed) PMID:18657324
DOI: Full-text: DOI:10.1016/j.jinf.2008.06.009

For viral infectious diseases, reliable biomarkers capable of monitoring recovery and therapeutic effects and that simultaneously discriminate between viral and bacterial infection are necessary. In this study, by using flow-cytometric quantification system, Toll-like receptor 2 (TLR2) expression levels on monocytes of influenza patients (n=47) were compared with those of healthy volunteers (n=50). Subsequently, throughout their acute, convalescent and healed phases, TLR2, C-reactive protein (CRP), serum amyroid A (SAA), and neopterin levels were followed. Additionally, TLR2 levels in other viral infectious diseases were assayed. The results showed that TLR2 level in influenza patients was remarkably up-regulated in acute phase compared to healthy volunteers (p<0.001). Thereafter, TLR2 levels normalized in good accordance with their recovery processes. CRP and neopterin levels were relatively widely distributed from normal to abnormally high levels in acute phase in spite of similar disease severity among the patients. SAA levels did not necessarily reflect the patients' clinical course during their recovery. Clinical observations of other viral infections also indicated that TLR2 levels were compatible with infection severity. TLR2 expression level on monocytes might serve as a unique biomarker useful in viral infectious diseases.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 4145339
Created: 2010-11-01
Species: All species
Last Modified: 2010-11-01
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.